nathan bwSteven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia

Play

CME/CE Information

Activity Title PH-IIP: Lessons for Optimizing Diagnosis and Treatment
Part 2: Treatment Approach
Topic Pulmonary Hypertension-Idiopathic Interstitial Pneumonias
Accreditation Type AMA PRA Category 1 Credits™
Release Date December 2014
Expiration Date December 31, 2015
Estimated Time to Complete Activity 15 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Summarize the current approach to the diagnosis and management of PH-IIP
  • Discuss current clinical trials in PH-IIP and treatments on the horizon

ACTIVITY FACULTY

Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
  6. Your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS


SPONSOR

This activity is sponsored by The France Foundation.


TARGET AUDIENCE

This activity is intended for pulmonologists, surgeons, critical care clinicians, pharmacists, advanced practice nurses, and other health care professionals involved in the management of patients with IPF.

STATEMENT OF NEED

Idiopathic interstitial pneumonias (IIPs) are a group of 8 recognized disorders that have distinct radiologic and histologic presentations and no identifiable cause. The most common IIP is idiopathic pulmonary fibrosis, and complications can include right-sided heart failure, respiratory failure, and pulmonary hypertension (PH). IIPs are generally distinguished from other diffuse parenchymal lung diseases on the basis of clinical properties, laboratory tests, physical examination, imaging, and histopathological features. Nevertheless, in some cases it is very hard to distinguish the condition from other diseases such as asbestosis, chronic hypersensitivity pneumonitis, autoimmune disorders, and sarcoidosis. In addition, the diagnosis of IIP should exclude other diffuse lung diseases such as emphysema or chronic obstructive lung disease, diffuse lung disease associated with occupational or environmental exposure, lymphangioleiomyomatosis, histiocytosis, and eosinophilic pneumonia.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty has indicated he has relationships with industry to disclose relative to the content of this CME activity:

  • Steven D. Nathan, MD, has received grants/research support from Actelion, Boehringer Ingelheim, InterMune, United Therapeutics, and Veracyte. He has served as a consultant for Actelion, Bayer Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, InterMune, Roche, and United Therapeutics. He has received honoraria from Actelion, Gilead Sciences, and United Therapeutics.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Bayer Global.

DISCLAIMER

The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Bayer Global assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

Play



Access other Therapeutic Areas: